Three drugs show sustained kidney function benefits in IgA nephropathy trials at 2 years
Atacicept, telitacicept, and sibeprenlimab demonstrated unprecedented benefits in stabilizing kidney function in phase 3 trials for IgA nephropathy, with sustained effects at two years.
